TLS is testing lisinopril as an adjunctive therapy in patients with MS; if clinical studies confirm its utility, as an inexpensive solution it might provide a real alternative for thousands suffering with MS

Please take part in designing an innovative clinical study of lisinopril in MS.

An Opportunity for Publication

All participants will be able to review and comment on drafts of the protocol as they are produced, and they will be mailed a TLS Development Team membership certificate to show their support for open innovation.

Participating in the Protocol Builder also enters you into a friendly competition among the research community. When we identify the researchers who have provided the best input for a certain section of the Protocol Builder, we will name them the winners of the section. This can be up to three participants per section.

By winning a section, researchers will enter into a discussion with the TLS study team on how to draft the best protocol. When this protocol is published, the top researchers will have co-authorship rights and an ongoing say into the design and implementation of the trial.

Rationale

It makes sense and the animal model has previously been proven predictive of clinical efficacy in this indication.

The critical activity of ACE on macrophages is also substantial for MS.

​Perhaps, since ACE inhibitors dilate blood vessels, the mechanism is similar to that proposed by Dr. Zamboni. If MS is associated with chronic cerebrospinal venous insufficiency (still to be proven), it is possible that if ACE inhibitors dilate jugular and azygous veins, cerebrospinal venous drainage might improve resulting in improvement in symptoms (the mechanism for this is unknown, Dr. Zamboni postulated a link to iron deposition.

We have reached a broad consensus on our rational. Do you have anything to add?

Patients

Researchers

Please click the rationale heading above to view the rationale. Then feel free to comment on it in the forum.

All respondants have answered that they agree. We're encouraged with these findings, but we'd like you to give us more detail in the forum. Was there one point in particular that you agreed with? Would you strike any aspects from the rationale?

Dose

20 to 40mg was favored slightly by researchers. Please see the full results to find the written-in responses, and feel free to comment in the forum.

Patients

Researchers

Patient respondents were asked if they ever needed a higher or lower dose of a medication, and most answered that they did not need an altered dose of any certain medication. Is this in line with your experience? Let us know in the forum.

We received a lot of researcher feedback on this topic. Make sure to check the full results at the top of the page.

Cybermonitoring

Researcher Telemedicine Results

Collection Method

Yes

No

Total

Accelerometer -- Peak Activity Index

6

1

7

Accelerometer -- Step Count

3

2

5

Actimeter

4

2

6

MAPS (Movement and Activity in Physical Space)

2

1

3

Telemedicine is a tenet of the TLS mission, and we received strong support for this strategy from both patients and researchers. Please view the full results of the Protocol Builders for the most in-depth display of the data.

Patients

Researchers

Patients were asked extensive questions on how telemedicine can be used in specific cases and with our specific endpoint. Please view the results of the Patient Protocol Builder to see the full data.

Telemonitoring is a pillar of our development process, and we are pleased to see such broad support from our researcher community. Please elaborate on your responses in the forum.